
Guido Oelkers to Depart Sobi CEO Role in 2027
After a decade of steering Swedish Orphan Biovitrum through its expansion into rare disease markets, CEO Guido Oelkers has notified the board of his intent to step down. The executive will maintain his leadership responsibilities through January 2027 to facilitate a handover to his eventual successor.





















